Viridian Therapeutics, Inc. (VRDN) Q4 2022 Earnings Call

Investor webinar replay

Replay transcript excerpt

Welcome to the Viridian Therapeutics fourth quarter and full year 2022 conference call. At this time, all participants are on a listen-only mode. Later, we will conduct a question and answer session and instructions will be given at that time. As a reminder, this conference is being recorded. I would now like to hand the floor over to Ms. Louisa Stone, Manager of Investor Relations at Viridian. Please go ahead. Thank you and welcome everyone to our fourth quarter and full year 2022 conference call. The press release reporting our financial results is available on the investors page of our corporate website at www.viridiantherapeutics.com. Joining me on the call this morning are Scott Myers, our President and Chief Executive Officer, Christian Humer, our Chief Financial and Business Officer, Dr. Deepa Rajagopalan, our Chief Product and Strategy Officer, and Todd James, Senior Vice President, Corporate Affairs and Investor Relations. Before we begin, I would like to remind everyone that this conference call and webcast will contain forward-looking statements regarding our financial outlook in addition to regulatory, product development, and commercialization plans and research activities. These statements are subject to risks and uncertainties that could cause actual results to materially differ from those forecasted. A description of these risks can be found in our most recent Form 10Q and 10K on file with the SEC. I would now like to turn the call over to Scott Myers, our President and CEO. Thank you, Elisa. Good morning, everyone. Thanks for joining us today. This is my first quarterly conference call since joining Viridian about a month ago. For those of you who are not familiar with my background, I've spent over 30 years in the pharmaceutical and medical technolo...